What is Pemvidutide?
Pemvidutide is Altimmune's experimental weekly injected peptide that activates GLP-1 and glucagon receptors in equal measure. It produced weight loss in a phase 2 obesity trial, and in a phase 2b trial in MASH it resolved the disease in about half of people but did not significantly improve liver scarring. It is not approved anywhere.
Video overview · 3:06
Pemvidutide: From Weight Loss to Fatty Liver and Alcohol. What the Trials Show
The MOMENTUM weight-loss trial, the "preserves muscle" claim, the IMPACT liver trial that missed its scarring goal, the early alcohol results, side effects and FDA status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Pemvidutide is an experimental GLP-1 and glucagon drug from Altimmune. It started out as a weight-loss drug, but its biggest results are now in fatty liver disease and alcohol use. Here's what the trials show, including the result that cut its stock in half.
Pemvidutide is a weekly injection that activates GLP-1 and glucagon receptors in equal measure. GLP-1 lowers appetite; glucagon is meant to burn more fat in the liver. Altimmune, a small US biotech, now develops it for fatty liver disease, alcohol use disorder and alcohol-related liver disease.
Here's the idea. GLP-1 lowers appetite. Glucagon pushes the liver to burn fat, and in trials liver fat did fall sharply. But whether that reverses liver scarring, which is what predicts outcomes, hasn't been shown.
In its 48-week weight-loss trial, MOMENTUM, 391 adults lost ten to sixteen percent of their weight, versus two percent on placebo. It still hasn't been published in a journal. The company says the drug spares muscle, but that comes from an MRI substudy of 50 people on the drug, with no placebo comparison.
In IMPACT, 212 people with biopsy-confirmed fatty liver disease, called MASH, the disease resolved in more than half, versus one in five on placebo. But the other key goal, less scarring, was missed: about a third improved, versus 28 percent on placebo. Altimmune's shares fell by more than half that day. In a small alcohol trial, heavy-drinking days fell more than on placebo.
Nausea was common: about half of people in the weight-loss trial, versus eleven percent on placebo, and about one in five on the higher doses quit because of side effects. In the liver trial, almost no one stopped. In the alcohol trial, ten percent quit for drug-related side effects, versus none on placebo.
Pemvidutide isn't approved anywhere. The FDA gave it breakthrough therapy status for MASH and fast track for alcohol use disorder, and a phase 3 liver trial of about 1,800 people started in 2026, with first results expected around 2029. Almost all of the data come from Altimmune itself.
Does it preserve muscle? Unproven: a small MRI substudy with no placebo comparison. Does it reverse liver scarring? Not shown: it missed that goal on biopsy. Does it cut drinking? Limited: one 24-week trial, reported by the company. And is it approved? No.
The bottom line: pemvidutide clears liver fat and resolved MASH in more than half of people in its phase 2b trial, but it missed the scarring goal, and its weight-loss data still aren't in a journal. For every study and source, see the pemvidutide profile on PepsRadar dot com, and subscribe for the next trial breakdown.
Biological role or research focus
Metabolic liver-disease research.
Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Role reference: Pemvidutide in MASLD, 12 weeks · J Hepatol 2025 ↗
Names you may encounter
ALT-801
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Dual GLP-1 / glucagon receptor agonist
- Research focus
- Metabolic liver-disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Pemvidutide FDA approved?
- No. No FDA-approved drug contains Pemvidutide. Source ↗
- Is Pemvidutide safe?
- Investigational GLP-1/glucagon drug, not FDA-approved. Phase 2 trials report mostly mild side effects, chiefly nausea, but were too small and short to rule out rare or long-term harms. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Pemvidutide banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| IMPACT (2025) | Human randomized trial | 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis. |
| Liver fat · 12 weeks (2025) | Human randomized trial | 94 adults with obesity and at least 10% liver fat; 29% had type 2 diabetes. |
| Liver fat · 24-week extension (2025) | Human randomized trial | 64 adults from the 12-week study who continued treatment. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2025
IMPACT
Did MASH resolve and did fibrosis improve?
- Population / model
- 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis.
- Study design
- Randomized placebo-controlled phase 2b study; this publication reports the 24-week analysis of a planned 48-week trial.
- Main finding
- MASH resolution without worsening fibrosis occurred in 58% and 52% of the pemvidutide groups versus 20% with placebo. Fibrosis improvement without worsening MASH was 33% and 36% versus 28%; these fibrosis comparisons were not statistically significant.
- Limits & context
- Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Human randomized trial · 2025
Liver fat · 12 weeks
Did pemvidutide reduce liver fat?
- Population / model
- 94 adults with obesity and at least 10% liver fat; 29% had type 2 diabetes.
- Study design
- Randomized, double-blind, placebo-controlled; three dose arms, 12 weeks.
- Main finding
- Liver fat fell by 46.6% to 68.5% relative to baseline versus 4.4% on placebo. Weight fell by up to 4.3%.
- Limits & context
- Liver fat on MRI is not the same as liver inflammation or scarring; most authors were company employees.
Human randomized trial · 2025
Liver fat · 24-week extension
Did the liver-fat reduction hold for 24 weeks?
- Population / model
- 64 adults from the 12-week study who continued treatment.
- Study design
- Extension of the randomized, placebo-controlled study to 24 weeks.
- Main finding
- At 24 weeks, liver fat had fallen by 56.3% to 76.4% versus 14.0% on placebo, and weight by up to 6.2%.
- Limits & context
- Small, short and company-authored; it does not measure scarring or clinical outcomes.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
16 registered studies name Pemvidutide as an intervention; 2 are recruiting or under way, 0 have not started recruiting yet, 10 completed and 4 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 16 listed studies.
Further reading · 2 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. ↗
Peptides · 2025 May · Journal Article, Review
Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. ↗
Journal of cachexia, sarcopenia and muscle · 2025 Dec · Journal Article
Read available full text ↗
Risks & interactions
Investigational GLP-1/glucagon drug, not FDA-approved. Phase 2 trials report mostly mild side effects, chiefly nausea, but were too small and short to rule out rare or long-term harms.
Phase 2 trials in people with fatty liver disease (24-week results reported) found adverse events in 78-81% on pemvidutide vs 67% on placebo, mostly mild or moderate, with few discontinuations. Longer and larger studies are needed.
Warnings for approved drugs in the same class (semaglutide, tirzepatide, liraglutide, dulaglutide), which may apply here too: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problemsBlood thinners or bleeding problemsHeart or blood pressure problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Interactions
- Anesthesia or sedation: GLP-1-based medicines slow stomach emptying, and reviews flag retained stomach contents as a class concern
Serious risks
- Pancreas and gallbladder problems are discussed as safety concerns for GLP-1-based medicines as a class
Side effects reported in studies
- nausea
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: IMPACT phase 2b trial in MASH: 24-week results (Lancet, 2025) ↗ · Pemvidutide in MASLD: randomized controlled study (J Hepatol, 2025) ↗ · Pemvidutide in MASH: GRADE-assessed meta-analysis (2026) ↗ · Efficacy and safety of GLP-1 medicines (review) ↗
What the featured evidence can tell us
Most adverse events were mild or moderate in the reported study. A phase 2b trial of this size and duration cannot establish long-term safety or uncommon harms.
Identity, route, and evidence limits
Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Side effects in the trials
Nausea and vomiting were common in the obesity trial, and about one in five people on the higher doses stopped because of side effects there. In the MASH trial, side-effect discontinuations were rare. In a small alcohol use disorder trial, 10% stopped for drug-related side effects versus none on placebo.
Source: IMPACT phase 2b MASH trial · Lancet 2025 ↗
Regulatory status
Pemvidutide is not approved anywhere. FDA granted it breakthrough therapy designation for MASH in 2026 and fast track designation for alcohol use disorder in 2025. Neither designation is an approval.
Source: IMPACT 48-week results and phase 3 plans · Altimmune 2025 (SEC filing) ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
Altimmune now develops pemvidutide for MASH, alcohol use disorder and alcohol-associated liver disease. A phase 3 MASH trial started in 2026, with 52-week results expected around 2029. Its 48-week obesity trial (MOMENTUM) has been reported only in company releases and at conferences, and the claim that it spares muscle rests on an MRI substudy of 50 people on the drug without a placebo comparison.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
GLP-1 activity lowers appetite. Glucagon activity is designed to push the liver to burn more fat and make less of it, which is why the program has moved toward fatty liver disease. In trials, liver fat measured by MRI fell sharply within 12 weeks, ahead of large changes in body weight.
Questions worth asking
- Did this study prove fibrosis reversal?
- What population, comparator, and route were actually studied?
- Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did this study prove fibrosis reversal?
No. The reported fibrosis-improvement comparisons did not reach statistical significance, even though MASH resolution was more frequent.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Does pemvidutide preserve muscle?
Not shown. The claim comes from an MRI substudy of 50 people on the drug with no placebo comparison, reported by the company rather than in a journal.
Source: MOMENTUM MRI body-composition substudy · Altimmune 2024 ↗
Does pemvidutide reduce alcohol use?
One 24-week phase 2 trial of 100 people reported fewer heavy-drinking days than placebo. It has been reported only in a company press release so far.
Source: RECLAIM topline results · Altimmune 2026 (SEC filing) ↗
References & editorial record
- PubMed · PMID 41237796 ↗
- Pemvidutide in MASLD, 12 weeks · J Hepatol 2025 ↗
- PERFORMA phase 3 MASH trial · ClinicalTrials.gov ↗
- MOMENTUM MRI body-composition substudy · Altimmune 2024 ↗
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial ↗
- MOMENTUM 48-week topline results · Altimmune 2023 ↗
- IMPACT 48-week results and phase 3 plans · Altimmune 2025 (SEC filing) ↗
- FDA · Concerns with unapproved GLP-1 drugs used for weight loss ↗
- RECLAIM topline results · Altimmune 2026 (SEC filing) ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
